share_log

NeuroSense Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Alon Ben-Noon(19.98%)

SEC announcement ·  Feb 13 10:19
Summary by Moomoo AI
Alon Ben-Noon, an Israeli citizen, has filed an amendment to Schedule 13G/A with the United States Securities and Exchange Commission, indicating a significant ownership stake in NeuroSense Therapeutics Ltd. As of December 31, 2023, Ben-Noon beneficially owns 3,072,600 ordinary shares of NeuroSense Therapeutics, which represents 19.98% of the company's class of securities. This stake includes 36,000 restricted share units that vested during the year. The filing, dated February 13, 2024, confirms that the information provided is true and complete to the best of Ben-Noon's knowledge after reasonable inquiry.
Alon Ben-Noon, an Israeli citizen, has filed an amendment to Schedule 13G/A with the United States Securities and Exchange Commission, indicating a significant ownership stake in NeuroSense Therapeutics Ltd. As of December 31, 2023, Ben-Noon beneficially owns 3,072,600 ordinary shares of NeuroSense Therapeutics, which represents 19.98% of the company's class of securities. This stake includes 36,000 restricted share units that vested during the year. The filing, dated February 13, 2024, confirms that the information provided is true and complete to the best of Ben-Noon's knowledge after reasonable inquiry.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more